{
  "id": 14188338,
  "title": "Incyte stock price target maintained at $152 by H.C. Wainwright",
  "url": "https://urgent.news/2026/10/13/incyte-stock-price-target-maintained-at-152-by-h-c-wainwright",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-13T11:32:47.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/incyte-stock-price-target-maintained-at-152-by-hc-wainwright-93CH-4946352"
  },
  "original_language": "en",
  "account": "Investing.com reports that H.C. Wainwright has maintained a Buy rating and $152 price target for Incyte (NASDAQ:INCY) stock. The firm cites competitive opportunities for Incyte's KRAS G12D-selective drug candidate INCB161734. The stock is trading at a low P/E ratio of 14.27 and PEG ratio of 0.18, indicating undervaluation. H.C. Wainwright analyzed FDA documents supporting the approval of Revolution Medicines' Rasonque (daraxonrasib) on October 8. The review showed a 24% response rate in KRAS G12D pancreatic ductal adenocarcinoma patients compared to 50% in G12V patients, with similar progression-free survival benefits. Incyte's drug INCB161734 has produced responses in 69% of previously untreated patients across chemotherapy combinations. The company's October 26 ESMO update will focus on response durability, disease control, and combination tolerability. H.C. Wainwright estimates potential sales of approximately $700 million annually, currently not included in the valuation. Incyte's financial health is rated as EXCELLENT by InvestingPro. Analysts have adjusted price targets for Incyte, with UBS at $127 (Neutral) and Stifel at $157 (Buy). H.C. Wainwright's updated target of $152 reflects the FDA approval of Atebrioz for fibrodysplasia ossificans progressiva, expected in October.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}